Chronix Biomedical appoints new chairman
This article was originally published in Clinica
Executive Summary
Chronix Biomedical, a company developing serum DNA-based blood tests to detect and manage cancer, has made Paul Freiman chairman of the board. Mr Freiman has over 30 years' experience in the pharmaceutical and biotech industry, including as CEO of Syntex and Neurobiological Technologies. He also serves on the board of Penwest Pharmaceuticals, Otsuka America Pharmaceuticals and NeoPharm. San Jose, California-based Chronix is developing blood tests that analyse DNA released into the blood by damaged and dying cells. They are designed to detect cancer at its earliest stages and track patients' responses to treatment. The company is currently advancing its technology through clinical validation towards commercialisation, and is seeking partners for further development.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.